StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Braftovi + Mektovi (encorafenib / binimetinib by Quarter

Braftovi + Mektovi (encorafenib / binimetinib — BRAF+ melanoma/CRC/NSCLC) — Worldwide revenues ($M) ($M)

QuarterlyAnnual

Pfizer Braftovi + Mektovi (encorafenib / binimetinib: $223M in Q2 2026, up 22.5% from a year earlier. That is the highest of the 14 quarters on record here.

Latest, Q2 2026
223
Period ended Jun 28, 2026
Change on a year earlier
+22.5%
182 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
10
Documents cited below

Where the Q2 2026 figure comes from

“|| Braftovi/Mektovi | 223 | 182 | 23% | 23% | 208 | 171 | 21% | 16 | 10 | 54% | 48%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBraftovi + Mektovi (encorafenib / binimetinib — BRAF+ melanoma/CRC/NSCLC) — Worldwide revenues ($M) ($M)Year on yearSource
Q2 2026Jun 28, 2026223+22.5%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 2026174+27.9%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 2025197+15.9%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 2025202+16.8%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 2025182+23.0%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2025Mar 30, 2025136+17.2%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2024Dec 31, 2024170+29.8%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2024Sep 29, 2024173+32.1%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 2024148+31.0%Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 2024116+12.6%Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 2023131–Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2023Oct 1, 2023131–Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2023Jul 2, 2023113–Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2023Apr 2, 2023103–Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗

Breakdown

What makes up braftovi + Mektovi (encorafenib / binimetinib

Cite this data

StockData. (2026). Pfizer Braftovi + Mektovi (encorafenib / binimetinib ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/braftovi-mektovi-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.